Advanced Medical Optics, Inc. and VISX, Incorporated Update Timeline on Expected Merger Completion
15 Fevereiro 2005 - 11:45PM
PR Newswire (US)
Advanced Medical Optics, Inc. and VISX, Incorporated Update
Timeline on Expected Merger Completion SANTA ANA, Calif. and SANTA
CLARA, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Advanced Medical
Optics, Inc. (AMO) (NYSE:AVO) and VISX, Incorporated (VISX)
(NYSE:EYE) today announced that they now expect to complete their
proposed merger during the second quarter of 2005. Earlier the
companies had indicated they were working to complete the merger
during the first quarter of 2005. The companies are awaiting the
completion of their respective year-end audited financial
statements, which are now required to be included in their joint
proxy statement/prospectus under applicable securities laws, prior
to scheduling their respective stockholder meetings and mailing the
joint proxy statement/prospectus to their stockholders. About
Advanced Medical Optics, Inc. Advanced Medical Optics, Inc. is a
global leader in the development, manufacturing and marketing of
ophthalmic surgical and eye care products. The company focuses on
developing a broad suite of innovative technologies and devices to
address a wide range of eye disorders. Products in the ophthalmic
surgical line include intraocular lenses, phacoemulsification
systems, viscoelastics, microkeratomes and related products used in
cataract and refractive surgery. AMO owns or has the rights to such
ophthalmic surgical product brands as Phacoflex(R), Clariflex(R),
Array(R), Sensar(R), CeeOn(R), Tecnis(R) and Verisyse(TM)
intraocular lenses, Sovereign(R) and Sovereign(R) Compact(TM)
phacoemulsification systems with WhiteStar(TM) technology,
Amadeus(TM) and Amadeus(TM) II microkeratomes, Healon(R) and
Vitrax(R) viscoelastics, and the Baerveldt(R) glaucoma shunt.
Products in the contact lens care line include disinfecting
solutions, daily cleaners, enzymatic cleaners and lens rewetting
drops. Among the contact lens care product brands the company
possesses are COMPLETE(R) Moisture PLUS(TM), COMPLETE(R)
Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1
Step, UltraCare(R), Ultrazyme(R), Total Care(R) and blink(TM)
branded products. Amadeus is a licensed product of, and a trademark
of, SIS, Ltd. AMO is based in Santa Ana, California, and employs
approximately 2,800 worldwide. The company has operations in about
20 countries and markets products in approximately 60 countries.
For more information, visit the company's Web site at
http://www.amo-inc.com/. About VISX, Incorporated VISX is a
worldwide market leader in the design, manufacture, and sale of
laser vision correction systems. The Company was founded in 1988
and received FDA approval for its first laser vision correction
product in 1996. VISX holds over 200 patents worldwide and has
licensed its technology to Alcon, Bausch & Lomb, LaserSight,
Nidek, Schwind, Zeiss-Meditec, and WaveLight Technologies. VISX
recently introduced the CustomVue(TM) procedure, a significant
advancement in laser vision correction that enables customized
corrections based on a comprehensive diagnostic measurement of the
optical errors in the eye. Clinical trial results show that the
CustomVue(TM) procedure has the potential to improve vision beyond
the correction possible with contacts and glasses. In the United
States alone there are 50 to 60 million eligible laser vision
correction candidates who experience some form of nearsightedness,
farsightedness, or astigmatism. VISX has a current effort underway
to treat presbyopia, the condition that requires reading glasses
with age, due to loss of accommodation for close work. Additional
information on VISX can be found on the worldwide web at
http://www.visx.com/. Additional Information and Where You Can Find
It On December 6, 2004, AMO filed a Registration Statement on Form
S-4, the most recent amendment to which was filed on February 14,
2005, with the SEC that includes a joint proxy statement/prospectus
of VISX and AMO and other relevant materials in connection with the
proposed transaction. The joint proxy statement/prospectus will be
mailed to the stockholders of VISX and AMO. Investors and security
holders of VISX and AMO are urged to read the joint proxy
statement/prospectus and the other relevant materials when they
become available because they will contain important information
about VISX, AMO and the proposed transaction. The joint proxy
statement/prospectus and other relevant materials, and any other
documents filed by VISX or AMO with the SEC, may be obtained free
of charge at the SEC's web site at http://www.sec.gov/. In
addition, investors and security holders may obtain free copies of
the documents filed with the SEC by VISX by contacting VISX
Investor Relations at or via telephone at (408) 773-7435. Investors
and security holders may obtain free copies of the documents filed
with the SEC by AMO at http://www.amo-inc.com/ or via telephone at
(714) 247-8348. Investors and security holders are urged to read
the joint proxy statement/prospectus and the other relevant
materials when they become available before making any voting or
investment decision with respect to the proposed transaction. VISX
and AMO and their respective directors and executive officers may
be deemed to be participants in the solicitation of proxies from
the stockholders of VISX and AMO in favor of the proposed
transaction. Information about the directors and executive officers
of VISX and AMO and their respective interests in the proposed
transaction will be available in the joint proxy
statement/prospectus. Cautionary Statement Regarding
Forward-Looking Statements This press release contains certain
forward-looking statements based on current expectations,
forecasts, and assumptions of AMO and VISX that involve risks and
uncertainties. Forward-looking statements in this release,
including statements relating to the timing of completion of the
merger, are based on information available to AMO and VISX as of
the date hereof. The following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: risks associated with uncertainty as to
whether the transaction will be completed, costs and litigation
associated with the merger, the failure to obtain the approval of
each company's stockholders, the inability to obtain, or meet
conditions imposed for, applicable tax requirements relating to the
merger, the failure of either party to meet the closing conditions
set forth in the definitive agreement, the ability to retain key
personnel before the merger, each company's ability to successfully
execute its business strategies, the extent and timing of
regulatory approvals, and the extent and timing of market
acceptance of new products or product indications, manufacturing,
litigation, the procurement, maintenance, enforcement and defense
of patents and proprietary rights, competitive conditions in the
industry, business cycles affecting the markets in which any
products may be sold, fluctuations in foreign exchange rates and
interest rates, and economic conditions generally or in various
geographic areas, including those set forth in AMO's and VISX's
most recent Annual Reports on Form 10-K and Quarterly Reports on
Form 10-Q, especially in the "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" sections, and their respective Current Reports on Form
8-K and other SEC filings. AMO and VISX are under no obligation to
(and expressly disclaim any such obligation to) update or alter
their forward-looking statements whether as a result of new
information, future events, or otherwise. Advanced Medical Optics:
Investor Contact: Sheree Aronson (714) 247-8290 Media Contact:
Steve Chesterman (714) 247-8711 VISX INCORPORATED: Investor/Media
Contact: Jackie Cossmon (408) 773-7435 DATASOURCE: Advanced Medical
Optics CONTACT: investors, Sheree Aronson, +1-714-247-8290, , or
media, Steve Chesterman, +1-714-247-8711, , both of Advanced
Medical Optics; or investors/media, Jackie Cossmon of VISX
INCORPORATED, +1-408-773-7435, Web site: http://www.amo-inc.com/
Copyright
Advanced medical Optics (NYSE:AVO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Advanced medical Optics (NYSE:AVO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024